New CellCelector CLD Takes You From Thousands of Candidates to the Top Clone, Faster

Key Takeaways

• Scans up to 885 nanowell plates, equivalent to 85,000 wells.
• Delivers 40% more monoclonal wells than standard plates.
• Generates 15,000 verified clones in four days.
• Achieves up to 100% transfer efficiency and viability.
• Cuts cell line development timeline to approximately seven weeks.

Pulse Analysis

The race to develop high‑producing monoclonal cell lines has long been a bottleneck for biologics manufacturers. Traditional workflows require manual microscopy, repetitive picking and extensive documentation, often stretching the screening phase to several months. In an industry where time‑to‑clinical‑trial can dictate market advantage, any technology that compresses this timeline while preserving data integrity is immediately valuable. Moreover, regulators such as the EMA demand full traceability of clone selection, pushing companies to adopt automated solutions that can generate auditable records without sacrificing scientific rigor.

The CellCelector CLD tackles those pain points with a three‑stage workflow: high‑speed scanning of up to 885 nanowell plates (the equivalent of 85,000 standard wells), real‑time imaging that identifies monoclonal wells and tracks growth, and a gentle retrieval module that transfers selected clones with up to 100% efficiency and viability. According to Sartorius, the platform delivers 40% more monoclonal wells and more than threefold higher outgrowth than conventional plates, enabling the production of up to 15,000 monoclonality‑verified clones in just four days. Integrated EMA‑410‑compliant productivity assays embed traceability at every decision point.

Accelerating clone selection translates directly into lower R&D expenditures and earlier entry into clinical phases, a competitive edge for both large pharma and emerging cell‑therapy developers. Sartorius’ broader cell line development ecosystem—encompassing instruments, consumables, reagents and media—allows customers to adopt the CLD without overhauling existing processes, further reducing implementation costs. With the company reporting 2025 revenues of roughly €3.4 billion (about $3.7 billion) and a global footprint of 14,000 employees, the CellCelector CLD reinforces its position as a leading supplier of automation solutions in the bioprocess market.